A modified gelatin comprising:

(a) lysine residues; and

(b) lysine residues comprising a pendent side chain carrying a thiol group;

wherein the modified gelatin comprises at least 50μmoles/g of component (b) and at least 450μmoles/g in total components (a) and (b). Also claimed are hydrogels, a process for making modified gelatins and kits comprising the modified gelatins and a crosslinking agent.

The invention relates to a method for peptide synthesis, wherein said method comprises the steps of reacting a first amino acid or a first peptide with an α-amine protected second amino acid in a solvent selected from the group consisting of water, alcohol, and a mixture of water and alcohol, and removing the α-amine protecting group with a deprotecting solution. The invention further relates to protective agents, their use and an apparatus for carrying out a method for solid phase synthesis of peptides.

The invention relates to a method for peptide synthesis, wherein said method comprises the steps of reacting a first amino acid or a first peptide with an α-amine protected second amino acid in a solvent selected from the group consisting of water, alcohol, and a mixture of water and alcohol, and removing the α-amine protecting group with a deprotecting solution. The invention further relates to protective agents, their use and an apparatus for carrying out a method for solid phase synthesis of peptides.

The present invention provides a method for producing a PNA oligomer. More specifically, the method comprises a step for reacting a PNA block and a PNA block in a solution to produce a PNA oligomer, and thus a PNA oligomer of interest can be produced with remarkably improved purity and yield.

The present invention provides a method for producing a PNA oligomer. More specifically, the method comprises a step for reacting a PNA block and a PNA block in a solution to produce a PNA oligomer, and thus a PNA oligomer of interest can be produced with remarkably improved purity and yield.

The present specification discloses a pharmaceutical composition for preventing or treating ophthalmopathy. More particularly, disclosed is a composition comprising a peptide derived from telomerase and being effective in treating and preventing ophthalmopathy. The disclosed peptide, a peptide having a sequence 80% identical to the sequence thereof, or a peptide as a fragment thereof is superiorly effective in treating ophthalmopathy.

An object to be achieved by the present in is to prepare a droplet using a protein that has not been known heretofore to form a droplet. The present invention provides a droplet including an assembly of a protein, wherein the protein is a PDI family protein and/or an artificial protein, and contains a thioredoxin-like domain.

An object to be achieved by the present in is to prepare a droplet using a protein that has not been known heretofore to form a droplet. The present invention provides a droplet including an assembly of a protein, wherein the protein is a PDI family protein and/or an artificial protein, and contains a thioredoxin-like domain.

An improved method for coupling amino acids into peptides or peptidomimetics is disclosed that includes the steps of combining an amino acid, a carbodiimide, an activator additive, and a base at less than 1 equivalent compared to the amino acid to be activated; and carrying out the activation and coupling at a temperature greater than 30° C.

Disclosed is a solid phase method of synthesizing biomolecule-drug-conjugates. In particular, this invention relates to a solid phase method of synthesizing antibody-drug-conjugates (ADCs). This invention also relates to intermediate methods of producing immobilized, chemically modified biomolecules, e.g., antibodies.